Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

What is claimed is:

1. (Previously presented) A compound comprising two or more antigen binding regions linked to at least one
prodrug-activating enzyme, wherein

a) the antigen binding region consists of a single polypeptide chain;

b) the single polypeptide chain is comprised of a first variable domain, a second variable domain, and a polypeptide linker connecting the first variable domain and the second variable domain, wherein a nucleotide sequence encoding the polypeptide linker is formed by two partially overlapping PCR primers during aPCR reaction that links the first variable domain and the second variable domain;

c) the compound has a bivalent or a multivalent structure; and wherein

d) the compound is glycosylated.

2. (Canceled).

3. (Previously presented) A compound as claimed in claim 1, wherein at least one antigen binding region comprises a variable domain of a heavy antibody chain and a variable domain of a light antibody chain (sFv fragment).

4. (Currently amended) A compound as claimed in claim 1, wherein ~~the antigen binding region~~ at least one of the antigen binding regions binds to a tumor-associated antigen (TAA).

5. (Previously presented) A compound as claimed in claim 3, wherein the TAA is selected from the group consisting of an N-CAM, PEM, EGF-R, Sialyl-Le^a, Sialyl-Le^X, TFβ, GICA, GD_3, GD_2, TAG72, CA125, the 24-25 kDa glycoprotein defined by MAb L6, and CEA.

6. (Previously presented) A compound as claimed in claim 1, wherein the enzyme is selected from the group consisting of a lactamase, pyroglutamate aminopeptidase, D-aminopeptidase, oxidase, peroxidase, phosphatase, hydroxynitrile lyase, protease, esterase, carboxypeptidase, and glycosidase.

7. (Previously presented) A compound as claimed in claim 6, wherein the enzyme is a β-glucuronidase, which is selected from the group consisting of an *E. coli* β-glucuronidase, a *Kobayasia nipponica* β-glucuronidase, a *Secale cereale* β-glucuronidase and a human β-glucuronidase.

8. (Currently amended) A compound as claimed in claim 1, wherein ~~the antigen binding region~~ at least one of the antigen binding regions is linked to the enzyme via a peptide linker.

9. (Currently amended) A compound as claimed in ~~claim 2, wherein the~~ claim 1, wherein glycosylation covalently bonds ~~the carbohydrates~~ carbohydrates to the compound, and the glycosylation takes place ~~either~~ by means of chemical methods ~~or by a selection of suitable expression systems~~.

10. (Previously presented) A compound as claimed in claim 1, which has undergone secretory expression in *Saccharomyces cerevisiae* or in *Hansenula polymorpha*.

11. (Previously presented) A compound as claimed in claim 1, which is expressed in *E. coli* and is subsequently chemically glycosylated.

12. (Previously presented) A compound as claimed in claim 30, wherein the sFv β-lactamase fusion protein has undergone periplasmic expression in *E. coli*, and is subsequently chemically glycosylated.

13. (Previously presented) A compound as claimed in claim 1, wherein the sFv β-lactamase fusion protein has undergone secretory expression in *Saccharomyces cerevisiae* or *Hansenula polymorpha*.

14. – 24. (Canceled).

25. (Previously presented) A pharmaceutical containing a compound as claimed in claim 1 and a physiologically acceptable carrier.

26. (Previously presented) A diagnostic aid comprising a compound as claimed in claim 1 .

27. (Previously presented) A compound as claimed in claim 6, wherein the lactamase enzyme is a *Bacillys cereus* β-lactamase II.

28. (Previously presented) A compound as claimed in claim 6, wherein the carboxypeptidase enzyme is a carboxypeptidase G2 from *Pseudomonas*.

29. (Previously presented) A compound as claimed in claim 10, which has undergone secretory expression in *Hansenula polymorpha*.

30. (Currently amended) A compound as claimed in claim 1, wherein ~~at least one antigen binding region and~~ the antigen binding regions and the at least one prodrug-activating enzyme form an sFv-β-lactamase fusion protein.

31. (Previously presented) A compound as claimed in claim 11, wherein the chemical glycosylation involves at least one of galactosylation or mannosylation.

32. (Previously presented) A compound as claimed in claim 12, wherein the chemical glycosylation involves at least one of galactosylation or mannosylation.

33. (Previously presented) A method of treating cancer comprising administering a compound claimed in claim 1 to a host in need thereof and subsequently administering a prodrug to be activated by the enzyme portion of the compound of claim 1.

34. (Previously presented) A compound comprising one or more antigen binding regions linked to at least one prodrug-activating enzyme, wherein

a) the antigen binding regions consist of a single polypeptide chain;

b) the single polypeptide chain is comprised of a first variable domain, a second variable domain, and a polypeptide linker connecting the first variable domain and the second variable domain, wherein a nucleotide sequence encoding the polypeptide linker is formed by two partially overlapping PCR primers during a PCR reaction that links the first variable domain and the second variable domain;

c) the compound has a monovalent, bivalent, or multivalent structure; and wherein

d) the compound is glycosylated.

35. (New) A compound as claimed in claim 2, wherein glycosylation covalently bonds carbohydrates to the compound, and the glycosylation takes place by a selection of suitable expression systems.